A rare case of extrarenal Wilms tumor of the uterine corpus: comprehensive genomic profile and review of the literature

被引:1
作者
Alessandrini, Lara [1 ]
Guerriero, Angela [1 ]
Munari, Giada [1 ,2 ]
Del Forno, Biancamaria [3 ]
Santoro, Luisa [1 ]
Marchetti, Matteo [4 ]
Nardin, Margherita [5 ]
Tozzi, Roberto [4 ]
Fassan, Matteo [3 ]
Dei Tos, Angelo Paolo [3 ]
机构
[1] Univ Hosp Padova, Surg Pathol Unit, Padua, Italy
[2] Ist Oncol Veneto IRCCS, Padua, Italy
[3] Univ Padua, Dept Med DIMED, Surg Pathol Cytopathol Unit, Padua, Italy
[4] Univ Padua, Dept Women & Childrens Hlth, Gynecol & Obstet Unit, Padua, Italy
[5] Ist Oncol Veneto IRCCS, Radiol Unit, Padua, Italy
关键词
endometrial rare histotypes; extra-renal wilms tumor; molecular pathology; UTERUS; PATHWAY;
D O I
10.32074/1591-951X-943
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Wilms tumor (WT), or nephroblastoma, is an uncommon malignant neoplasm occurring in the kidney of pediatric patients. Its extrarenal location is extremely rare and has been reported in various sites, including the female genital tract, with only 9 cases arising in the uterine corpus. We present the case of an adult woman who underwent total abdominal hysterectomy due to a uterine mass causing persistent abdominal pain. The characteristic triphasic morphology (composed of epithelial, stromal, and blastemal elements) supported by a broad immunohistochemical panel, along with the imaging exclusion of a renal neoplasm, was diagnostic of WT of the uterus. For the first time, a comprehensive genomic profiling of a uterine primary WT was also performed by next-generation sequencing, disclosing alterations at the level of copy number variations in the genes ERBB2, FGFR23, FGF6, FGFR2, and RPS6KB1. All previously reported uterine cases were reviewed, with a summary of their main clinicopathologic characteristics, and the main differential diagnoses are presented. Further reports are needed to improve our knowledge about prognostic factors, clinical behavior and molecular alterations that could guide appropriate therapeutic decision making.
引用
收藏
页码:333 / 340
页数:8
相关论文
共 27 条
[1]  
[Anonymous], 2022, NCCN CLIN PRACTICE G, V1
[2]  
BABAIAN RJ, 1980, CANCER-AM CANCER SOC, V45, P1713, DOI 10.1002/1097-0142(19800401)45:7<1713::AID-CNCR2820450732>3.0.CO
[3]  
2-U
[4]  
BECKWITH JB, 1978, CANCER-AM CANCER SOC, V41, P1937, DOI 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO
[5]  
2-U
[6]  
BITTENCOURT AL, 1981, CANCER-AM CANCER SOC, V47, P2496, DOI 10.1002/1097-0142(19810515)47:10<2496::AID-CNCR2820471031>3.0.CO
[7]  
2-V
[8]   Review of phase I and II trials for Wilms' tumour - Can we optimise the search for novel agents? [J].
Brok, Jesper ;
Pritchard-Jones, Kathy ;
Geller, James I. ;
Spreafico, Filippo .
EUROPEAN JOURNAL OF CANCER, 2017, 79 :205-213
[9]   Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer [J].
Brooks, A. Nigel ;
Kilgour, Elaine ;
Smith, Paul D. .
CLINICAL CANCER RESEARCH, 2012, 18 (07) :1855-1862
[10]  
Cao Minmin, 2017, Chinese Medical Sciences Journal, V32, P274, DOI 10.24920/J1001-9294.2017.040